ATE348615T1 - 2-(4-(2-hydroxymethyl-phenylamino)-piperidin-1- yl)-n-(9h-carbazol-3-yl) - acetamid derivate und verwandte verbindungen als neuropeptide y5 (npy5) liganden zur behandlung von fettleibigkeit - Google Patents

2-(4-(2-hydroxymethyl-phenylamino)-piperidin-1- yl)-n-(9h-carbazol-3-yl) - acetamid derivate und verwandte verbindungen als neuropeptide y5 (npy5) liganden zur behandlung von fettleibigkeit

Info

Publication number: ATE348615T1
Authority: AT; Austria
Prior art keywords: npy5; carbazol; neuropeptide; phenylamino; obesity
Prior art date: 2003-07-30

Application number

AT04741322T

Other languages

English (en)

Inventor

Jover Antoni Torrens

Prio Josep Mas

Zueras Alberto Dordal

Escasany Maria Angeles Fisas

Helmut Heinrich Buschmann

Original Assignee

Esteve Labor Dr

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-30

Filing date

2004-07-29

Publication date

2007-01-15

2004-07-29 Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr

2007-01-15 Application granted granted Critical

2007-01-15 Publication of ATE348615T1 publication Critical patent/ATE348615T1/de

Links

208000008589 Obesity Diseases 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
239000003446 ligand Substances 0.000 title 1
GXYZYLVOXZTOFN-UHFFFAOYSA-N n-(9h-carbazol-3-yl)-2-[4-[2-(hydroxymethyl)anilino]piperidin-1-yl]acetamide Chemical class OCC1=CC=CC=C1NC1CCN(CC(=O)NC=2C=C3C4=CC=CC=C4NC3=CC=2)CC1 GXYZYLVOXZTOFN-UHFFFAOYSA-N 0.000 title 1
235000020824 obesity Nutrition 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Manufacturing & Machinery (AREA)
Ceramic Engineering (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Hematology (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Structural Engineering (AREA)
Immunology (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Materials Engineering (AREA)
Cardiology (AREA)
Inorganic Chemistry (AREA)
Nutrition Science (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT04741322T 2003-07-30 2004-07-29 2-(4-(2-hydroxymethyl-phenylamino)-piperidin-1- yl)-n-(9h-carbazol-3-yl) - acetamid derivate und verwandte verbindungen als neuropeptide y5 (npy5) liganden zur behandlung von fettleibigkeit ATE348615T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
ES200301813A ES2222833B1 (es)	2003-07-30	2003-07-30	Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos.

Publications (1)

Publication Number	Publication Date
ATE348615T1 true ATE348615T1 (de)	2007-01-15

Family

ID=34130546

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT04741322T ATE348615T1 (de)	2003-07-30	2004-07-29	2-(4-(2-hydroxymethyl-phenylamino)-piperidin-1- yl)-n-(9h-carbazol-3-yl) - acetamid derivate und verwandte verbindungen als neuropeptide y5 (npy5) liganden zur behandlung von fettleibigkeit
AT04763608T ATE348614T1 (de)	2003-07-30	2004-07-29	2-(4-(phenylamino)-piperidin-1-yl)-n-phenyl- acetamid derivate und verwandte verbindungen als neuropeptid y5 (npy5) liganden zur behandlung von fettleibigkeit

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT04763608T ATE348614T1 (de)	2003-07-30	2004-07-29	2-(4-(phenylamino)-piperidin-1-yl)-n-phenyl- acetamid derivate und verwandte verbindungen als neuropeptid y5 (npy5) liganden zur behandlung von fettleibigkeit

Country Status (19)

Country	Link
US (4)	US20070105853A1 (de)
EP (2)	EP1651220B1 (de)
JP (2)	JP2007500169A (de)
CN (2)	CN1829516A (de)
AR (1)	AR045154A1 (de)
AT (2)	ATE348615T1 (de)
AU (2)	AU2004262482A1 (de)
BR (2)	BRPI0413091A (de)
CA (2)	CA2534101A1 (de)
DE (2)	DE602004003829T2 (de)
ES (3)	ES2222833B1 (de)
MX (2)	MXPA06001140A (de)
MY (1)	MY136965A (de)
NO (2)	NO20060553L (de)
PE (1)	PE20050332A1 (de)
PT (2)	PT1651220E (de)
RU (2)	RU2006105792A (de)
TW (1)	TW200510379A (de)
WO (2)	WO2005013988A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9560804B1 (en)	2010-12-15	2017-02-07	Marion Calmer	Stalk roll with flutes defining a recess
ES2222833B1 (es) *	2003-07-30	2006-03-01	Laboratorios Del Dr. Esteve, S.A.	Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos.
EP1918281A1 (de) *	2006-11-02	2008-05-07	Laboratorios del Dr. Esteve S.A.	Phenylamino-substituierte piperidine Verbindungen, ihre Herstellung und Verwendung als Arzneimittel
WO2008103310A1 (en)	2007-02-16	2008-08-28	Synta Pharmaceuticals Corp.	Substituted fused-ring compounds for inflammation and immune-related uses
US20110230497A1 (en) *	2008-11-07	2011-09-22	H. Lundbeck A/S	Biologically active amides
CA3191437A1 (en) *	2020-08-11	2022-02-17	Board Of Trustees Of Michigan State University	Proteasome enhancers and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997019682A1 (en)	1995-12-01	1997-06-05	Synaptic Pharmaceutical Corporation	Aryl sulfonamide and sulfamide derivatives and uses thereof
AU7692996A (en)	1995-12-01	1997-06-27	Ciba-Geigy Ag	Receptor antagonists
WO1998024768A1 (en)	1996-12-03	1998-06-11	Banyu Pharmaceutical Co., Ltd.	Novel urea derivatives
US6048900A (en) *	1998-02-13	2000-04-11	Bayer Corporation	Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
EP0910565A1 (de) *	1997-02-14	1999-04-28	Bayer Corporation	Amidderivate als selektive neuropeptid-y-rezeptoren
AU6309698A (en)	1997-03-12	1998-09-29	Banyu Pharmaceutical Co., Ltd.	Drugs containing aminopyridine derivatives as the active ingredient
US7534857B2 (en) *	1997-12-19	2009-05-19	Centegen, Inc.	Methods and compositions for the treatment and prevention of staphylococcal infections
US6187777B1 (en)	1998-02-06	2001-02-13	Amgen Inc.	Compounds and methods which modulate feeding behavior and related diseases
EP1119543B1 (de)	1998-10-07	2004-12-15	Ortho-McNeil Pharmaceutical, Inc.	N-aralkylaminotetraline als neuropeptid-y-y5-rezeptorliganden
US6399631B1 (en) *	1999-07-23	2002-06-04	Pfizer Inc.	Carbazole neuropeptide Y5 antagonists
WO2001007409A1 (en) *	1999-07-23	2001-02-01	Astrazeneca Uk Limited	Carbazole derivatives and their use as neuropeptide y5 receptor ligands
DK1202986T3 (da) *	1999-07-28	2006-02-20	Ortho Mcneil Pharm Inc	Amin- og amidderivater som ligander for neuropeptid Y-Y5-receptoren, der er nyttige ved behandlingen af obesitet og andre lidelser
AU769081B2 (en)	1999-08-26	2004-01-15	Bristol-Myers Squibb Company	NPY antagonists: spiroisoquinolinone derivatives
SK287726B6 (en) *	2001-07-24	2011-07-06	Richter Gedeon Vegyeszet	Carboxylic acid amide derivatives, their preparation, pharmaceutical compositions containing them and process for preparing pharmaceutical compositions
US7067549B2 (en) *	2001-12-31	2006-06-27	Actelion Pharmaceuticals Ag	Pyrrolidone carboxamides
ES2193875B2 (es) *	2002-04-09	2005-03-01	Laboratorios Del Dr. Esteve, S.A.	Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
ES2228267B1 (es) *	2003-07-30	2006-07-01	Laboratorios Del Dr. Esteve, S.A.	Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
ES2222833B1 (es) *	2003-07-30	2006-03-01	Laboratorios Del Dr. Esteve, S.A.	Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos.

2003
- 2003-07-30 ES ES200301813A patent/ES2222833B1/es not_active Expired - Fee Related
2004
- 2004-07-29 MY MYPI20043075A patent/MY136965A/en unknown
- 2004-07-29 JP JP2006521533A patent/JP2007500169A/ja active Pending
- 2004-07-29 AU AU2004262482A patent/AU2004262482A1/en not_active Abandoned
- 2004-07-29 RU RU2006105792/04A patent/RU2006105792A/ru unknown
- 2004-07-29 CN CNA2004800219418A patent/CN1829516A/zh active Pending
- 2004-07-29 DE DE602004003829T patent/DE602004003829T2/de not_active Expired - Lifetime
- 2004-07-29 WO PCT/EP2004/008508 patent/WO2005013988A1/en not_active Ceased
- 2004-07-29 JP JP2006521526A patent/JP2007500162A/ja active Pending
- 2004-07-29 ES ES04763608T patent/ES2279419T3/es not_active Expired - Lifetime
- 2004-07-29 BR BRPI0413091-0A patent/BRPI0413091A/pt not_active Application Discontinuation
- 2004-07-29 EP EP04741322A patent/EP1651220B1/de not_active Expired - Lifetime
- 2004-07-29 MX MXPA06001140A patent/MXPA06001140A/es not_active Application Discontinuation
- 2004-07-29 AR ARP040102696A patent/AR045154A1/es unknown
- 2004-07-29 PT PT04741322T patent/PT1651220E/pt unknown
- 2004-07-29 TW TW093122665A patent/TW200510379A/zh unknown
- 2004-07-29 AT AT04741322T patent/ATE348615T1/de not_active IP Right Cessation
- 2004-07-29 US US10/566,399 patent/US20070105853A1/en not_active Abandoned
- 2004-07-29 CA CA002534101A patent/CA2534101A1/en not_active Abandoned
- 2004-07-29 MX MXPA06001226A patent/MXPA06001226A/es not_active Application Discontinuation
- 2004-07-29 RU RU2006105711/04A patent/RU2006105711A/ru unknown
- 2004-07-29 ES ES04741322T patent/ES2279400T3/es not_active Expired - Lifetime
- 2004-07-29 CA CA002534096A patent/CA2534096A1/en not_active Abandoned
- 2004-07-29 US US10/565,979 patent/US7888510B2/en not_active Expired - Fee Related
- 2004-07-29 AU AU2004262491A patent/AU2004262491A1/en not_active Abandoned
- 2004-07-29 EP EP04763608A patent/EP1648458B1/de not_active Expired - Lifetime
- 2004-07-29 BR BRPI0412860-5A patent/BRPI0412860A/pt not_active IP Right Cessation
- 2004-07-29 AT AT04763608T patent/ATE348614T1/de not_active IP Right Cessation
- 2004-07-29 CN CNA2004800222637A patent/CN1832745A/zh active Pending
- 2004-07-29 WO PCT/EP2004/008517 patent/WO2005013990A1/en not_active Ceased
- 2004-07-29 DE DE602004003831T patent/DE602004003831T2/de not_active Expired - Lifetime
- 2004-07-29 PT PT04763608T patent/PT1648458E/pt unknown
- 2004-08-02 PE PE2004000734A patent/PE20050332A1/es not_active Application Discontinuation
2006
- 2006-02-02 NO NO20060553A patent/NO20060553L/no not_active Application Discontinuation
- 2006-02-07 NO NO20060605A patent/NO20060605L/no not_active Application Discontinuation
2010
- 2010-07-12 US US12/834,211 patent/US20100280072A1/en not_active Abandoned
2011
- 2011-01-06 US US12/985,646 patent/US20110172270A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NO20060605L (no)	2006-02-07
PE20050332A1 (es)	2005-06-12
US20070105853A1 (en)	2007-05-10
WO2005013988A8 (en)	2006-11-09
EP1648458A1 (de)	2006-04-26
TW200510379A (en)	2005-03-16
CN1829516A (zh)	2006-09-06
BRPI0412860A (pt)	2006-10-03
ES2222833B1 (es)	2006-03-01
US20110172270A1 (en)	2011-07-14
CA2534101A1 (en)	2005-02-17
MXPA06001226A (es)	2006-05-15
ES2222833A1 (es)	2005-02-01
EP1651220B1 (de)	2006-12-20
JP2007500162A (ja)	2007-01-11
JP2007500169A (ja)	2007-01-11
CA2534096A1 (en)	2005-02-17
PT1651220E (pt)	2007-03-30
AU2004262482A1 (en)	2005-02-17
NO20060553L (no)	2006-02-02
PT1648458E (pt)	2007-03-30
DE602004003829D1 (de)	2007-02-01
DE602004003829T2 (de)	2007-09-20
DE602004003831D1 (de)	2007-02-01
RU2006105792A (ru)	2007-09-20
CN1832745A (zh)	2006-09-13
EP1648458B1 (de)	2006-12-20
US20100280072A1 (en)	2010-11-04
WO2005013990A1 (en)	2005-02-17
RU2006105711A (ru)	2007-09-20
DE602004003831T2 (de)	2007-10-25
EP1651220A1 (de)	2006-05-03
MXPA06001140A (es)	2006-04-24
AU2004262491A1 (en)	2005-02-17
MY136965A (en)	2008-12-31
US7888510B2 (en)	2011-02-15
ES2279400T3 (es)	2007-08-16
BRPI0413091A (pt)	2006-10-03
US20080119516A1 (en)	2008-05-22
ATE348614T1 (de)	2007-01-15
ES2279419T3 (es)	2007-08-16
AR045154A1 (es)	2005-10-19
WO2005013988A1 (en)	2005-02-17

Legal Events

Date

Code

Title

Description

2007-11-15

UEP

Publication of translation of european patent specification

Ref document number: 1651220

Country of ref document: EP

2010-04-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE365039T1 (de)	2007-07-15	4-(4-(heterocyclylalkoxy phenyl)-1-(heterocyclyl- carbonyl)piperidin derivate und verwandte verbindungen als histamin h3 antagonsiten zur behandlung von neurologischen erkrankungen wie alzheimer's
DE602004009323D1 (de)	2007-11-15	1-(2-amino-benzoyl)-piperazin-derivate als glycin-aufnahmehemmer zur behandlung von psychosen
ATE447559T1 (de)	2009-11-15	4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3- carboxamid derivate als mek inhibitoren zur behandlung von hyperproliferativen erkrankungen
NO20055714D0 (no)	2005-12-02	Inhibitorer av fosfatidylinositol 3-kinase
ATE501721T1 (de)	2011-04-15	Chinolin-derivate zur behandlung von latenter tuberkulose
SI3153514T1 (sl)	2022-02-28	Kinazolinoni kot zaviralci človeške fosfatidilinozitol 3-kinaze delta
DE602006008945D1 (de)	2009-10-15	Isochinolinderivate als inhibitoren von rho-kinase
ATE550338T1 (de)	2012-04-15	Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
DE602004022187D1 (de)	2009-09-03	4-(pyrazol-3-ylamino)pyrimidinderivate zur verwendung bei der behandlung von krebs
ATE405553T1 (de)	2008-09-15	Heterocyclische verbindungen als inhibitoren von faktor viia
NO20054317D0 (no)	2005-09-20	Fremgangsmate for homogenisering av polyolefin-DRA-midler
DE602006017980D1 (de)	2010-12-16	3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
NO20080265L (no)	2008-01-15	2-(1H-indolylsulfanyl)-arylaminderivater
MA28394B1 (fr)	2007-01-02	Derives d'heteroaryle pour traitement des virus
DE60332862D1 (de)	2010-07-15	17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen
DE602005017373D1 (de)	2009-12-10	Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten
DE502004009690D1 (de)	2009-08-13	4-(3- (2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butansäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose
DE60232719D1 (de)	2009-08-06	Kombination enthaltend einen inhibitor der signaltransduktion und ein epothilonderivat
ATE348615T1 (de)	2007-01-15	2-(4-(2-hydroxymethyl-phenylamino)-piperidin-1- yl)-n-(9h-carbazol-3-yl) - acetamid derivate und verwandte verbindungen als neuropeptide y5 (npy5) liganden zur behandlung von fettleibigkeit
ATE504580T1 (de)	2011-04-15	Malonsäureamidderivate als inhibitoren von g- sekretase zur behandlung von alzheimer-krankheit
DE602004006118D1 (de)	2007-06-06	2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
ATE525355T1 (de)	2011-10-15	1-ä(4-äbenzoyl(methyl)aminoü-3- (phenyl)butylüazetidinderivate zur behandlung von gastrointestinalen erkrankungen 1
MX2009003974A (es)	2009-04-27	N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)pi peridin-4-ilideno)metil)benzamida, el proceso para su sintesis, asi como su uso para el tratamiento del dolor, la ansiedad y la depresion.
ATE426596T1 (de)	2009-04-15	N-(phenyl-oxazol-4-ylmethoxymethyl)-cyclohexyl- bernsteinsaureamid derivate und verwandte verbindungen als ppar-liganden (peroxisomen- proliferatoren-aktivierte rezeptoren) zur behandlung von hyperlipidamie und diabetes
ATE337779T1 (de)	2006-09-15	N-'4-(2-imino-pyrrolidin-1-yl)phenyl)-acetemid- und entsprechende piperidinderivate als faktor xa inhibitoren zur behandlung von thromboembolischen erkrankungen